Power Law company profile

Myovant Sciences

Biotech & Life Sciences · Brisbane, United States · Founded 2016 · IPO 2016 Unicorn

Women’s health and endocrine diseases medicines. Subsidiary of Roivant

Valuation

$2.72B

Market cap · 2026

Revenue

$405M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Global footprint

Where Myovant Sciences has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States96.4%

🇦🇷 Argentina1.8%

🇨🇭 Switzerland1.8%

3 countries shown

Web traffic by country

180 monthly visits
across markets

🇺🇸 United States111.1%

Top 1 markets shown

Patent intelligence

$77M patent portfolio · 18 active families

Estimated portfolio value

$77M

2.8% of market cap · 26.2× smaller than top peer Ablynx ($2B)

18 active patent families

Where Myovant Sciences innovates TetrahydrothiophenePyridazinePyrimidinePharmaceutical drugAmino radical

Where Myovant Sciences concentrates vs peers

Each axis is a top-10 topic across Myovant Sciences and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Myovant Sciences

An AI-synthesized read of the highest-engagement posts about Myovant Sciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Myovant Sciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles